Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

NCT00040768 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

35

Enrollment

NIH

Sponsor class

Stopped Administratively complete.

Conditions

Recurrent Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer

Interventions

DRUG: bortezomib

Sponsor

National Cancer Institute (NCI)